dr. rule on rituximab biosimilar use in the uk
Published 6 years ago • 245 plays • Length 1:23Download video MP4
Download video MP3
Similar videos
-
1:39
dr. wierda on role of rituximab biosimilar in evolving cll treatment paradigm
-
1:03
dr. eradat on rituximab biosimilar in cd20 b-cell nhl and cll
-
1:29
dr. goy discusses the rituximab biosimilar fda approval
-
2:11
dr. lyman on rituximab biosimilars in non-hodgkin lymphoma
-
2:15
dr. danilov on utility of rituximab biosimilars in cll
-
0:53
biosimilar rituximab in the treatment of cll
-
1:12
an audit of infusion-related reactions with biosimilar rituximab in london
-
17:14
evaluation of tnf inhibitor biosimilar use in the uk: a study from badbir - dr zenas yiu
-
1:31
simon rule, md: subcutaneous rituximab versus an intravenous biosimilar
-
38:15
biosimilars and biologics
-
2:03
dr. lugtenburg on maintenance rituximab in dlbcl
-
0:48
rituximab and its biosimilars: consistencies and advantages
-
3:07
raising awareness of the benefits of biosimilars in the uk
-
1:21
explaining biosimilars to our patients
-
5:56
the complexity of choosing biosimilars in oncology
-
0:54
dr. brufsky discusses reasons to use biosimilars in oncology
-
1:28
the role of pharmacists when introducing biosimilar monoclonal antibodies into practice
-
0:52
dr. ansell on fda approval of subcutaneous rituximab in select blood cancers
-
0:59
audit of rapid infusion of biosimilar rituximab